Articles By Wayne Koberstein, Executive Editor

-
Companies To Watch: Corner Therapeutics2/1/2023
Corner Therapeutics is focused on discovering new small molecules that could mimic the body’s natural immune response to generate the robust T-cell response.
-
Companies To Watch: Ocelot Bio1/3/2023
Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.
-
Biopharma Public Opinion, Pricing, Politics12/1/2022
Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.
-
Companies To Watch: iTolerance11/1/2022
iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.
-
Pioneering In-House, Continuous Manufacturing11/1/2022
Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.
-
Companies To Watch: CytoAgents10/3/2022
CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.
-
The Discovering CEO10/3/2022
In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.
-
Companies To Watch: Viking Therapeutics9/1/2022
Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.
-
Nonprofit Pursues Oncology Drugs9/1/2022
RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.
-
Companies To Watch: Priothera8/1/2022
Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.
-
Living Diversity, Inside Mink Therapeutics8/1/2022
We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.
-
Companies To Watch: Mirum Pharmaceuticals7/1/2022
Mirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.
-
New Space For Bio In Transplantation7/1/2022
Jasper Therapeutics and other bio companies may revolutionize hematopoietic stem cell therapy (HSCT) — a feat with profound effects on the biopharma and hospital-based hematology sectors alike.
-
Companies To Watch: CinCor Pharma6/1/2022
CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.